VTVT stock surges on licensing deal for diabetes candidate (NASDAQ:VTVT)
seekingalpha.com
finance
2022-06-01 11:51:51

Eoneren/E+ via Getty Images Clinical-stage biotech vTv Therapeutics (NASDAQ:VTVT) climbed ~87% in the pre-market Wednesday after the company announced a collaboration and license agreement with affiliates of UAE-based health tech firm G42 Healthcare for its lead candidate TTP399 targeted at type 1 diabetes. Per the terms vTv (VTVT) and an affiliate of G42 will jointly conduct clinical trials for pharmaceutical products containing TTP399. In addition, G42 affiliate will partially fund a portion of the Phase 3 clinical trials for TTP399.
